Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

Ann Hematol. 2009 Mar;88(3):281-2. doi: 10.1007/s00277-008-0597-2. Epub 2008 Aug 26.

Authors

A Galanopoulos, S I Papadhimitriou, E Kritikou-Griva, M Georgiakaki, N I Anagnostopoulos

PMID: 18726593
DOI: 10.1007/s00277-008-0597-2

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / adverse effects*
Benzamides
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Multiple Myeloma / chemically induced*
Multiple Myeloma / diagnosis
Multiple Myeloma / etiology
Piperazines / adverse effects*
Pyrimidines / adverse effects*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate